Business Context and Reporting Period
Company: China Jo-Jo Drugstores, Inc. (Note: Input metadata referenced "Ridgetech Inc.", but the filing text identifies the registrant as China Jo-Jo Drugstores, Inc.)
Filing Type: Form 6-K (Interim Financial Statements)
Reporting Period: Six months ended September 30, 2024 (Unaudited)
Business Overview: The Company operates four segments in China: retail drugstores (132 locations as of Sept 30, 2024), online pharmacy, wholesale distribution, and farming of traditional Chinese medicine (TCM) herbs. The farming segment generated no revenue during the period.
Key Financial Metrics
| Metric | Six Months Ended Sept 30, 2024 | Six Months Ended Sept 30, 2023 |
|---|---|---|
| Net Revenue | $71,159,724 | $78,574,409 |
| Gross Profit | $14,597,432 | $15,933,089 |
| Gross Margin | 20.5% | 20.3% |
| Operating Loss | $(2,222,730) | $255,982 (Income) |
| Net Loss | $(2,277,092) | $(924,261) |
| Loss Per Share (Basic/Diluted) | $(0.42) | $(0.77) |
| Cash & Equivalents (End of Period) | $18,001,171 | $20,149,806 |
| Total Cash & Restricted Cash | $31,092,907 | $29,600,320 |
| Working Capital | $3,544,243 | $(4,677,733) |
| Notes Payable (Current) | $32,689,034 | $31,676,335 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 9.4% ($7.4M) year-over-year. This was driven by a 26.6% drop in wholesale revenue ($6.9M) and a 9.9% drop in online sales ($1.6M), partially offset by a 3.0% increase in retail drugstore sales ($1.1M).
- Operating Performance: The Company shifted from an operating income of $256k in the prior period to an operating loss of $2.2M. This deterioration was caused by increased General and Administrative (G&A) expenses and lower gross profit volume.
- Expense Increases: G&A expenses surged 66.4% ($1.1M increase), primarily due to a reduction in bad debt allowance reversals compared to the prior year. Selling expenses remained relatively flat, increasing only 0.4%.
- Cash Flow: Operating cash flow turned negative, using $9.95M compared to providing $0.72M in the prior period. This was largely due to decreases in accounts payable and increases in inventory and receivables. Financing activities provided $7.8M, primarily through equity issuance ($7.6M) and net debt activity.
Outlook, Risks, and Management Commentary
- Segment Strategy: Management expects retail drugstore sales to continue growing due to new store openings and marketing initiatives. However, online sales face intense competition and price transparency, limiting near-term growth. The wholesale segment is pivoting toward modern online platforms to access broader markets and improve negotiating power.
- Margin Pressure: Retail gross margins decreased (29.3% vs 31.4%) due to government insurance price adjustments and competitive market pressures. Management notes that unless the economy recovers, high retail margins may not be sustainable.
- Liquidity: The Company maintains a positive working capital position of $3.5M. Total cash and restricted cash stands at approximately $31.1M.
- Subsequent Events: In October and November 2024, the CEO and CFO surrendered a total of 473,215 ordinary shares for no consideration, which were immediately cancelled by the Company.
- Risks: Key risks include intense competition in online and wholesale markets, reliance on government insurance pricing, and the long growth cycle of the farming segment (ginkgo trees).
Investor Verification Checklist
- Revenue Mix Shift: Verify the sustainability of the wholesale revenue decline and the success of the pivot to online wholesale platforms.
- Bad Debt Reversals: Confirm the accounting treatment and future expectations regarding bad debt allowances, which significantly impacted G&A expenses.
- Debt Obligations: Review the terms and maturity of the $32.7M in current notes payable to assess near-term liquidity requirements.
- Equity Dilution: Note the significant increase in share count (from ~1.7M to ~6.6M shares) due to recent equity issuances and its impact on per-share metrics.
- Inventory Levels: Monitor inventory growth ($2.5M increase) relative to sales velocity to ensure no obsolescence risks.